

Retinal Degeneration - Pipeline Insight, 2018

<https://marketpublishers.com/r/R9ACF41167EEN.html>

Date: October 2018

Pages: 217

Price: US\$ 1,500.00 (Single User License)

ID: R9ACF41167EEN

Abstracts

This report can be delivered to the clients within 48 hours

'Retinal Degeneration- Pipeline Insight, 2018' report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Retinal Degeneration. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 150+ products along with 120+ companies involved.

Products covered by Phase

Phase III, Phase II and Phase I

Pre-clinical and Discovery

Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Retinal Degeneration

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Retinal Degeneration

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE OF THE REPORT

Provides an overview of therapeutic pipeline activity for Retinal Degeneration across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Retinal Degeneration therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information

Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Coverage of dormant and discontinued pipeline projects across Retinal Degeneration

REASONS TO BUY

Establish a comprehensive understanding of the current pipeline scenario across Retinal Degeneration to formulate effective R&D strategies

Assess challenges and opportunities that influence Retinal Degeneration R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Retinal Degeneration to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

of the report

Provides an overview of therapeutic pipeline activity for Retinal Degeneration across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Retinal Degeneration therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information

Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration

Coverage of dormant and discontinued pipeline projects across Retinal Degeneration

Contents

Overview: Retinal Degeneration
Age-Related Macular Degeneration
Symptoms & Diagnosis
Treatment Options
Retinitis Pigmentosa
Symptoms & Diagnosis
Treatment
Stargardt Disease
Symptoms & Diagnosis
Treatment
Pipeline Therapeutics (Clinical Stage Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Abicipar: Allergan
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical & Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
Appendix

List Of Tables

LIST OF TABLES

- Table 1: Total Products for Retinal Degeneration
- Table 2: Late Stage Products (Phase III)
- Table 3: Mid Stage Products (Phase II)
- Table 4: Early Stage Products (Phase I)
- Table 5: List of Pre-clinical & Discovery Products
- Table 6: Assessment by Product Type
- Table 7: Assessment by Stage and Product Type
- Table 8: Assessment by Route of Administration
- Table 9: Assessment by Stage and Route of Administration
- Table 10: Assessment by Molecule Type
- Table 11: Assessment by Stage and Molecule Type
- Table 12: List of Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1: Fundus photographs of healthy and AMD affected eyes
- Figure 2: Fundus photographs of healthy and RP affected eyes
- Figure 3: Color photo and auto fluorescent fundus image of Stargardt disease
- Figure 4: Total Products for Retinal Degeneration
- Figure 5: Late Stage Products (Phase III)
- Figure 6: Mid Stage Products (Phase II)
- Figure 7: Early Stage Products (Phase I)
- Figure 8: Pre-clinical & Discovery Stage Products
- Figure 9: Assessment by Product Type
- Figure 10: Assessment by Stage and Product Type
- Figure 11: Assessment by Route of Administration
- Figure 12: Assessment by Stage and Route of Administration
- Figure 13: Assessment by Molecule Type
- Figure 14: Assessment by Stage and Molecule Type
- Figure 15: Inactive Products

I would like to order

Product name: Retinal Degeneration - Pipeline Insight, 2018

Product link: <https://marketpublishers.com/r/R9ACF41167EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9ACF41167EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970